Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.50 |
| ▸ | CA9 | Q16790 | 16/20 | 0.50 |
| ▸ | CA12 | O43570 | 15/20 | 0.50 |
| ▸ | CA1 | P00915 | 15/20 | 0.50 |
| ▸ | CA4 | P22748 | 7/20 | 0.42 |
| ▸ | CA7 | P43166 | 7/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618348 | 0.89 | IDH2 (0.45) | CA2CA9TRPV1LMNAMAPT | |
| SCHEMBL17618807 | 0.89 | PLG (0.44) | CA2CA9CA12CA1LMNA | |
| SCHEMBL16250003 | 0.89 | CA2 (0.42) | CA2CA9CA12CA1MAPT | |
| SCHEMBL17618783 | 0.89 | MEN1 (0.47) | TRPV1LMNAMAPTHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16238420 | 0.88 | CA2 (0.42) | CA2CA9CA12CA1MAPT | |
| SCHEMBL17618902 | 0.88 | CA2 (0.42) | CA2CA9TRPV1LMNAMAPT | |
| SCHEMBL17618906 | 0.88 | CA2 (0.42) | CA2CA9TRPV1LMNAMAPT | |
| SCHEMBL17618817 | 0.87 | CA2 (0.41) | CA2CA9TRPV1LMNAGAA | |
| SCHEMBL17618793 | 0.87 | NPY2R (0.43) | CA2CA9TRPV1LMNAGAA | |
| SCHEMBL17618792 | 0.86 | CA2 (0.45) | CA2CA9TRPV1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA2 4636/4885CA9 4430/4885CA12 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.